ALZHEIMER'S DISEASE
Assessing the safety and efficacy of an investigational medication to slow or halt the progression of Alzheimer’s disease. Prospective subjects should be reasonably healthy with mild to moderate Alzheimer’s disease. It is also important to have a caregiver (spouse, child, friend) who can accompany the patient to the clinic for visits. Compensation is provided for time and travel.
PAINFUL DIABETIC NEUROPATHY
Assessing the safety and efficacy of an investigational medication in the treatment of painful symptoms (pins and needles, burning, shooting pains, jabbing pains, etc) that accompany diabetic neuropathy.
POST-HERPTIC NEURALGIA
Assessing the safety and efficacy of an investigational medication in the treatment of persisting pain following the occurrence of Shingles (Herpes-Zoster). Pain must be present for at least 3 months after the disappearance of the rash.
RESTLESS LEGS SYNDROME
Assessing the safety and efficacy of an investigational medication in the treatment of RLS. The symptoms of RLS include: an irresistible urge to move the legs, occurring mostly evening and night time, relieved by moving.
ACUTE MIGRAINE
Assessing the safety and efficacy of an investigational medication to abort or limit the symptoms of migraine headache attack.
MIGRAINE PREVENTION
Assessing the safety and efficacy of an investigational medication to prevent or limit the frequency and intensity of migraine attacks.
